GLP-1 Medication Access 2024: Options & Clinical Pathways

Last reviewed: May 19, 2026

Last updated: May 19, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Yes, GLP-1 medications remain accessible through multiple clinical pathways, including compounded formulations from licensed 503A pharmacies. Unlike branded options that faced supply constraints, compounded GLP-1 products offer consistent availability while maintaining quality standards through licensed pharmacy networks.

Understanding your access options involves more than availability—it requires evaluating which treatment may align with your metabolic profile and clinical needs. Precision-wellness approaches that incorporate biomarker context and genetic predisposition data can help support a more informed conversation with your healthcare provider about which GLP-1 option may be appropriate for you.

Why GLP-1 Access Has Evolved: Supply, Demand, and Clinical Options

Branded GLP-1 medications like Ozempic, Wegovy, and Mounjaro experienced significant demand surges starting in 2022, creating intermittent supply challenges. Compounded versions from licensed 503A pharmacies emerged as a consistent alternative, manufactured under strict pharmaceutical guidelines while offering sustained accessibility.

The shift toward compounded options reflects broader healthcare strategy. Licensed 503A compounders can adjust dosing, formulation, and supply more flexibly than manufacturers of branded drugs, making them valuable for patients seeking reliable access or those whose clinical needs require customized dosing protocols.

Compounded vs. Branded GLP-1 Options: What Patients Should Know

Both compounded and branded GLP-1 medications work through the same mechanism—activating GLP-1 receptors to reduce appetite and support metabolic regulation. The key difference lies in manufacturing, sourcing, and regulatory oversight. Compounded medications are produced in 503A pharmacies under USP standards; branded versions are manufactured by pharmaceutical companies and FDA-approved for specific indications.

Factor	Compounded (503A Pharmacy)	Branded (FDA-Approved)
Manufacturing	Licensed compounding pharmacy under USP standards	Pharmaceutical manufacturer (FDA-regulated)
Availability	Generally consistent; adjustable to demand	Subject to manufacturer supply decisions
Dosing Flexibility	Can customize concentrations and formulations	Fixed doses per FDA approval
Cost Range	Semaglutide $149/mo; Tirzepatide $249/mo	Typically $900–$1,500/mo depending on insurance
Clinical Use	Prescribed off-label for weight management under provider direction	FDA-approved for diabetes (some) or weight management (branded versions)

How Biomarker and Genetic Context Informs Your GLP-1 Decision

Genetic variants in GLP-1 receptor pathways, FTO gene expression, and GIPR signaling influence how individuals metabolize and respond to GLP-1 therapy. Understanding your genetic predispositions—such as variants in GLP1R rs6923761, GIPR rs1800437, and MC4R rs17782313—may help provide context for why certain dosing strategies or formulations could be more aligned with your metabolic profile.

Biomarker testing for GLP-1 response is not predictive of exact outcomes, but it can support a more personalized conversation with your healthcare provider. The Precision Peptide Genetic Test ($99 add-on or $298 standalone) reveals predispositions in peptide genetic pathways, helping your provider assess baseline metabolic factors and adjust treatment strategy accordingly.

Who Should Consider GLP-1 Therapy and Safety Considerations

GLP-1 medications are medically indicated for individuals with type 2 diabetes or obesity (BMI ≥30) and prescribed off-label under provider supervision for weight management. Candidates typically benefit from GLP-1 if they have metabolic syndrome markers, insulin resistance, or inadequate response to lifestyle modification. However, contraindications exist: personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, or pregnancy.

Starting GLP-1 therapy requires baseline medical assessment, including metabolic panels, thyroid function, and gastric motility evaluation. Common side effects include nausea, vomiting, and diarrhea, typically resolving within weeks. A qualified healthcare provider should evaluate your candidacy, baseline health status, and medication interactions before initiating any GLP-1 formulation—whether compounded or branded.

How PlexusDx Supports a More Personalized Approach

PlexusDx compounded GLP-1 options—semaglutide, tirzepatide, and our dual-compound GLP-Squared—are manufactured through licensed 503A pharmacies, ensuring consistent quality and reliable availability. These formulations allow providers to tailor dosing and delivery method (injectable or oral) based on your clinical presentation and metabolic needs, supporting a more individualized approach than fixed-dose branded alternatives.

The Precision Peptide Genetic Test may help provide context about your baseline peptide pathway function and genetic predispositions relevant to GLP-1 response. Key variants analyzed include GLP1R, GIPR, FTO, and MC4R genes—each influencing appetite regulation, metabolic rate, and receptor sensitivity. This data should be interpreted with a qualified healthcare provider to inform treatment selection and dosing strategy.

Combining genetic insight with clinical evaluation supports a more informed provider conversation about whether compounded GLP-1, oral formulations, or microdose protocols align best with your metabolic profile, lifestyle, and clinical goals. PlexusDx facilitates this precision-wellness approach by connecting genetic predisposition data with accessible, compounded medication options.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.